Clinical and Functional Effects of Inhaled Dual Therapy Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease: A Real-Life Study

References

• Barnes PJ, Burney PG, Silverman EK, et al. Chronic obstructive pulmonary disease. Nat Rev Dis Primers. 2015;1:15076. doi:10.1038/nrdp.2015.76
   PubMed Web of Science ®Google Scholar
• Blanco I, Diego I, Bueno P, Casas-Maldonado F, Miravitlles M. Geographic distribution of COPD prevalence in the world displayed by geographic information system maps. Eur Respir J. 2019;54(1):1900610. doi:10.1183/13993003.00610-2019
   PubMed Web of Science ®Google Scholar
• Christenson SA, Smith BM, Bafadhel M, Putcha N. Chronic obstructive pulmonary disease. Lancet. 2022;399(10342):2227–2242. doi:10.1016/S0140-6736(22)00470-6
   PubMed Web of Science ®Google Scholar
• Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442. doi:10.1371/journal.pmed.0030442
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Laveneziana P. The clinical importance of dynamic lung hyperinflation in COPD. COPD. 2006;3(4):219–232. doi:10.1080/15412550600977478
   PubMedGoogle Scholar
• O’Donnell DE. Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006;3(2):180–184. doi:10.1513/pats.200508-093DO
   PubMedGoogle Scholar
• Ni Y, Yu Y, Dai R, Shi G. Diffusing capacity in chronic obstructive pulmonary disease assessment: a meta-analysis. Chron Respir Dis. 2021;18:14799731211056340. doi:10.1177/14799731211056340
   Web of Science ®Google Scholar
• Wedzicha JA, Decramer M, Seemungal TA. The role of bronchodilator treatment in the prevention of exacerbations of COPD. Eur Respir J. 2012;40(6):1545–1554. doi:10.1183/09031936.00048912
   PubMed Web of Science ®Google Scholar
• Matera MG, Page CP, Cazzola M. Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. Trends Pharmacol Sci. 2011;32(8):495–506. doi:10.1016/j.tips.2011.04.003
   PubMed Web of Science ®Google Scholar
• Cazzola M, Page CP, Calzetta L, Matera MG. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64(3):450–504. doi:10.1124/pr.111.004580
   PubMed Web of Science ®Google Scholar
• Cazzola M, Tashkin DP. Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function. COPD. 2009;6(5):404–415. doi:10.1080/15412550903156333
   PubMedGoogle Scholar
• Coulson FR, Fryer AD. Muscarinic acetylcholine receptors and airway diseases. Pharmacol Ther. 2003;98(1):59–69. doi:10.1016/S0163-7258(03)00004-4
   PubMed Web of Science ®Google Scholar
• Malerba M, Foci V, Patrucco F, et al. Single inhaler LABA/LAMA for COPD. Front Pharmacol. 2019;10:390. doi:10.3389/fphar.2019.00390
   PubMed Web of Science ®Google Scholar
• Pelaia G, Vatrella A, Busceti MT, et al. Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD. Ther Clin Risk Manag. 2015;11:1563–1572. doi:10.2147/TCRM.S84151
   PubMed Web of Science ®Google Scholar
• Rogliani P, Calzetta L, Braido F, et al. LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review. Int J Chron Obstruct Pulmon Dis. 2018;13:3115–3130. doi:10.2147/COPD.S170606
   PubMed Web of Science ®Google Scholar
• Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 62. 5/25mcg in COPD. Respir Med. 2013;107(10):1538–1546. doi:10.1016/j.rmed.2013.06.001
   PubMed Web of Science ®Google Scholar
• Maleki-Yazdi MR, Kaelin T, Richard N, Zvarich M, Church A. Efficacy and safety of umeclidinium/vilanterol 62. 5/25mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med. 2014;108(12):1752–1760. doi:10.1016/j.rmed.2014.10.002
   PubMed Web of Science ®Google Scholar
• Kerwin EM, Kalberg CJ, Galkin DV, et al. Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study. Int J Chron Obstruct Pulmon Dis. 2017;12:745–755. doi:10.2147/COPD.S119032
   PubMed Web of Science ®Google Scholar
• Maltais F, Bjermer L, Kerwin EM, et al. Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. Respir Res. 2019;20(1):238. doi:10.1186/s12931-019-1193-9
   PubMed Web of Science ®Google Scholar
• Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis management and prevention of COPD. goldcopd.org/2023; 2023.
   Google Scholar
• Graham BL, Steenbruggen I, Miller MR, et al. Standardization of spirometry 2019 update. An official American thoracic society and European respiratory society technical statement. Am J Respir Crit Care Med. 2019;200(8):e70–e88. doi:10.1164/rccm.201908-1590ST
   PubMed Web of Science ®Google Scholar
• Graham BL, Brusasco V, Burgos F, et al. 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung. Eur Respir J. 2017;49(1):1600016. doi:10.1183/13993003.00016-2016
   PubMed Web of Science ®Google Scholar
• Scott LJ, Hair P. Umeclidinium/vilanterol: first global approval. Drugs. 2014;74(3):389–395. doi:10.1007/s40265-014-0186-8
   PubMed Web of Science ®Google Scholar
• Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54(7):581–586. doi:10.1136/thx.54.7.581
   PubMed Web of Science ®Google Scholar
• Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34(3):648–654. doi:10.1183/09031936.00102509
   PubMed Web of Science ®Google Scholar
• Kim V, Aaron SD. What is a COPD exacerbation? Current definitions, pitfalls, challenges and opportunities for improvement. Eur Respir J. 2018;52(5):1801261. doi:10.1183/13993003.01261-2018
   PubMed Web of Science ®Google Scholar
• Cada DJ, Ingram K, Leonard J, Baker DE. Umeclidinium bromide and vilanterol trifenatate inhalation powder. Hosp Pharm. 2014;49(6):554–562. doi:10.1310/hpj4906-554
   PubMedGoogle Scholar
• Cazzola M, Segreti A, Matera MG. New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol. Drug Des Devel Ther. 2013;7:1201–1208. doi:10.2147/DDDT.S39449
   PubMed Web of Science ®Google Scholar
• Armentaro G, Pelaia C, Cassano V, et al. Association between right ventricular dysfunction and adverse cardiac events in mild COPD patients. Eur J Clin Invest. 2022;53:e13887. doi:10.1111/eci.13887
   PubMed Web of Science ®Google Scholar
• Casarosa P, Bouyssou T, Germeyer S, Schnapp A, Gantner F, Pieper M. Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs. J Pharmacol Exp Ther. 2009;330(2):660–668. doi:10.1124/jpet.109.152470
   PubMed Web of Science ®Google Scholar
• Somlyo AP, Somlyo AV. Signal transduction and regulation in smooth muscle. Nature. 1994;372(6503):231–236. doi:10.1038/372231a0
   PubMed Web of Science ®Google Scholar
• Pérez Fontan JJ. On lung nerves and neurogenic injury. Ann Med. 2002;34(4):226–240. doi:10.1080/078538902320322493
   PubMed Web of Science ®Google Scholar
• Groneberg DA, Quarcoo D, Frossard N, Fischer A. Neurogenic mechanisms in bronchial inflammatory diseases. Allergy. 2004;59(11):1139–1152. doi:10.1111/j.1398-9995.2004.00665.x
   PubMed Web of Science ®Google Scholar
• Gross NJ, Co E, Skorodin MS. Cholinergic bronchomotor tone in COPD. Estimates of its amount in comparison with that in normal subjects. Chest. 1989;96(5):984–987. doi:10.1378/chest.96.5.984
   PubMed Web of Science ®Google Scholar
• Hall IP. Second messengers, ion channels and pharmacology of airway smooth muscle. Eur Respir J. 2000;15(6):1120–1127. doi:10.1034/j.1399-3003.2000.01523.x
   PubMed Web of Science ®Google Scholar
• Salmon M, Luttmann MA, Foley JJ, et al. Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J Pharmacol Exp Ther. 2013;345(2):260–270. doi:10.1124/jpet.112.202051
   PubMed Web of Science ®Google Scholar